World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents.
The efficacy of direct-acting antiviral (DAA) agents against hepatitis C virus (HCV) infection can be compromised by substitutions in the HCV genome that occur before treatment (resistance-associated substitutions, RAS). We performed a meta-analysis to determine the prevalence of RASs and their effects. We searched publication databases for studies of HCV RNA substitutions that mediate resistance to DAAs. Findings from 50 studies of the prevalence of RAS in HCV, from 32 countries, were used in a meta-analysis. We retrieved the HCV RNA sequence from the Los Alamos HCV sequence database to estimate the prevalence of the RASs. The degree of resistance to treatment conferred by each RAS was determined based on fold-change in the 50% effective concentration of the drugs (EC50 value). Our final analysis included data from of 49,744 patients with HCV infection and 12,612 HCV sequences. We estimated the prevalence of 56 RASs that encoded amino acids and 114 specific RASs. The average prevalence of RASs was highest in HCV genotype (GT) 6, followed by HCV GT1a, GT2, GT1b, GT3, and GT4. The highest prevalence of RASs observed encoded Q80K in NS3-NS4A of HCV GT1a, Y93T in NS5A of GT1a, and C316N in NS5B of GT1b. The greatest number of RASs were observed at D168 in NS3-NS4A, at Y93 in NS5A, and at C316 in NS5B. The prevalence of RASs and mutation burden were high in Japan, the United States, Germany, Thailand, and the UK; low in Russia, Brazil, Egypt, and India; and intermediate in China, Canada, Australia, Spain, and France. In a meta-analysis, we found evidence for 114 RASs in HCV of different HCV genotypes. Patients with HCV infection should be tested for RASs before treatment is selected -especially in regions with a high prevalence of RASs.